ReviewInvestigative ophthalmology & visual science2013
A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders.
Review in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Soft matrix promotes ciliogenesis in human retinal pigment epithelial cells.Scientific reports · 2026Article
- Osteopontin Regulates AQP4 Expression by TRPV4 Activation in Müller Cells: Implications for Retinal Homeostasis.Molecular neurobiology · 2025Article
- Fibrotic Changes in Rhegmatogenous Retinal Detachment.International journal of molecular sciences · 2025Review
- Expression of Versican in the Retina and Its Implication in Retinal Disease.Advances in experimental medicine and biology · 2025Review
- miR-210 is essential to retinal homeostasis in fruit flies and mice.Biology direct · 2024Article
- CD44 signaling in Müller cells impacts photoreceptor function and survival in healthy and diseased retinas.Journal of neuroinflammation · 2024Article
- Article
- Endothelial Notch Signaling Regulates the Function of the Retinal Pigment Epithelial Barrier via EC Angiocrine Signaling.Antioxidants (Basel, Switzerland) · 2023Article
- Identification of the zebrafish homologues of IMPG2, a retinal proteoglycan.Cell and tissue research · 2023Article
- Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases.Aging and disease · 2023Review
- Retinal Metabolic Profile on IMPG2 Deficiency Mice with Subretinal Lesions.Advances in experimental medicine and biology · 2023Article
- Voluntary exercise modulates pathways associated with amelioration of retinal degenerative diseases.Frontiers in physiology · 2023Article
- Extracellular Matrix: The Unexplored Aspects of Retinal Pathologies and Regeneration.Advances in experimental medicine and biology · 2023Review
- Müller Glia maintain their regenerative potential despite degeneration in the aged zebrafish retina.Aging cell · 2022Article
- A Comparative Analysis of the Camera-like Eyes of Jumping Spiders and Humans.Vision (Basel, Switzerland) · 2021Review
- Effect of NK-5962 on Gene Expression Profiling of Retina in a Rat Model of Retinitis Pigmentosa.International journal of molecular sciences · 2021Article
- Modulation of SOD3 Levels Is Detrimental to Retinal Homeostasis.Antioxidants (Basel, Switzerland) · 2021Article
- The killifish visual system as an in vivo model to study brain aging and rejuvenation.NPJ aging and mechanisms of disease · 2021Article
- Genetic Rescue of X-Linked Retinoschisis Mouse (Human gene therapy · 2021Article
- Maturation and Protection Effect of Retinal Tissue-Derived Bioink for 3D Cell Printing Technology.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Progressive inherited retinal degenerative disorders (PIRDDs) are the leading cause of blindness in developed countries, with AMD and RP constituting the majority of PIRDDs. Currently, over 8 million Americans have PIRDDs, and that number is estimated to drastically increase by the end of this decade. Although a mutant protein is expressed starting early during retinal development in patients with PIRDDs, symptoms of retinal degeneration do not manifest until much later. Historically, research has focused on understanding the role a mutation has in the function of a protein and what role the mutant protein has in the disease process. However, it remains unknown why the disease, irrespective of the mutation, manifests clinically much later in life, while cellular indicators of disease (e.g., accumulation of toxic protein products and cell death) occur throughout early and middle life. Herein, we propose that there exists a time point at which the degenerative process is accelerated, leading to the appearance of clinical symptoms. This point is defined by structural disruptions of the extracellular matrix (ECM). Death of a critical number of ECM-maintaining mutant protein-expressing retinal cells contributes to that break point in the degenerative process. Therefore, it is important to understand the changes occurring at the ECM during PIRDDs and to take that into account when therapeutic approaches are designed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.